OSE Immunotherapeutics to Present Novel FPR2 Agonist Antibody at AAI 2026

First-in-class monoclonal antibody aims to trigger natural inflammation resolution mechanisms for chronic diseases.

Apr. 15, 2026 at 7:48am

Got story updates? Submit your updates here. ›

An ethereal, ghostly X-ray image revealing the intricate internal structure of a human immune cell receptor, conveying the innovative scientific approach behind OSE Immunotherapeutics' novel FPR2 agonist therapy.A groundbreaking new antibody therapy aims to harness the body's natural inflammation resolution pathways to treat chronic diseases.Boston Today

OSE Immunotherapeutics, a clinical-stage biotech company, announced that an abstract on a novel agonist monoclonal antibody targeting FPR2, a key receptor involved in resolving inflammation, has been selected for an oral presentation at the 2026 Annual Meeting of the American Association of Immunologists (AAI) in Boston. The company's Chief Scientific Officer, Aurore Morello, PhD, will unveil this first-in-class therapeutic strategy that aims to activate the body's natural inflammation-resolution mechanisms for treating chronic inflammatory diseases.

Why it matters

Chronic inflammatory diseases represent significant unmet medical needs globally, but current treatments often focus on long-term suppression of the immune system rather than restoring physiological balance. OSE's FPR2 agonist approach reflects a shift toward 'resolution biology', which has the potential to open new therapeutic opportunities and build differentiated, durable value in the treatment of inflammation.

The details

The FPR2-targeting monoclonal antibody developed by OSE Immunotherapeutics is designed to switch off inflammation and actively trigger the resolution of inflammation by limiting neutrophil recruitment and reprogramming macrophages to a pro-resolutive, anti-inflammatory state. The company's preclinical data has demonstrated robust efficacy of this first-in-class FPR2 agonist in multiple inflammatory disease models.

  • The oral presentation at the AAI 2026 meeting will take place on April 17, 2026 from 9:45-10:00 EST.
  • OSE Immunotherapeutics plans to unveil the novel FPR2 agonist monoclonal antibody for the first time at the AAI 2026 meeting.

The players

OSE Immunotherapeutics

A clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation.

Aurore Morello, PhD

Chief Scientific Officer of OSE Immunotherapeutics, who will present the novel FPR2 agonist monoclonal antibody at the AAI 2026 meeting.

Got photos? Submit your photos here. ›

What they’re saying

“Chronic inflammatory diseases are associated with significant unmet medical needs on a global scale, yet current treatments largely focus on long‑term suppression of immune cells rather than restoration of physiological balance.”

— Aurore Morello, PhD, Chief Scientific Officer, OSE Immunotherapeutics

“Our strategy targeting the FPR2 receptor reflects a deliberate shift toward resolution biology—an area with the potential to open new therapeutic opportunities and build differentiated, durable value in inflammation.”

— Aurore Morello, PhD, Chief Scientific Officer, OSE Immunotherapeutics

What’s next

OSE Immunotherapeutics plans to present detailed preclinical data on the novel FPR2 agonist monoclonal antibody at the AAI 2026 meeting, which could pave the way for future clinical development of this first-in-class therapeutic approach.

The takeaway

OSE Immunotherapeutics' focus on 'resolution biology' and targeting the FPR2 receptor represents a novel therapeutic strategy that aims to actively trigger the body's natural inflammation resolution mechanisms, potentially offering new hope for patients suffering from chronic inflammatory diseases.